Introduction
Immunoglobulin G (IgG) represents the most abundant antibody class in human serum, constituting approximately 75 % of the total circulating immunoglobulins. IgG molecules mediate a wide range of immune functions, including neutralization of pathogens, opsonization, complement activation, and antibody-dependent cellular cytotoxicity. The ability of IgG to cross the placental barrier confers passive immunity to the fetus and early infant life. Because of its central role in immunity, IgG serves as a key biomarker in diagnostics, a therapeutic target, and a scaffold for engineered biologics. This article provides a comprehensive overview of IgG, covering its discovery, structural biology, functional roles, clinical significance, and contemporary research directions.
History and Discovery
The concept of antibodies dates back to the 19th century, but it was not until the early 1900s that specific antibody classes were distinguished. In 1907, the Austrian scientist Hans Thaller first described a “globulin” fraction in serum with bactericidal activity. Subsequent electrophoretic analyses in the 1930s revealed distinct antibody components, leading to the nomenclature of IgG, IgM, IgA, IgD, and IgE. The identification of the Fc receptor (FcRn) in 1970s provided a mechanistic explanation for the longevity of IgG and its transplacental transport. Modern molecular cloning and monoclonal antibody technology in the 1970s and 1980s enabled detailed characterization of IgG subclasses and paved the way for therapeutic antibody development.
Throughout the 20th century, advances in immunochemistry, such as isoelectric focusing and high-performance liquid chromatography, refined the classification of IgG subclasses (IgG1–IgG4). The advent of recombinant DNA technology facilitated the production of monoclonal IgG antibodies for both research and therapeutic use, establishing IgG as a cornerstone of modern medicine.
Structural and Functional Characteristics
Gene Organization
Human IgG genes reside on chromosome 14q32.3 and consist of variable (V), diversity (D), joining (J), and constant (C) segments that recombine during B‑cell development. The heavy-chain locus contains separate constant region genes for each IgG subclass: IGHG1, IGHG2, IGHG3, and IGHG4. Each constant domain comprises three immunoglobulin-like subdomains (CH1, CH2, CH3) linked by flexible hinge regions. The light chains, either kappa or lambda, contribute additional variable domains that pair with the heavy chain to form antigen-binding sites.
Subclasses and Structural Diversity
IgG subclasses differ in hinge length, glycosylation patterns, and Fc receptor affinity. IgG1 and IgG3 exhibit longer hinge regions, conferring higher flexibility and avidity for multivalent antigens. IgG2 and IgG4 possess shorter hinges, which influence antigen-binding orientation and effector function. The Fc region of each subclass engages Fcγ receptors (FcγR) and the complement component C1q with subclass-specific affinities, thereby modulating downstream immune pathways.
Binding Properties
The antigen-binding fragment (Fab) contains the V domains of both heavy and light chains. Complementarity-determining regions (CDRs) within the V domains form the paratope, which recognizes a specific epitope on the antigen. The constant domain of the Fc fragment mediates interactions with FcγRs, the neonatal Fc receptor (FcRn), and the complement system. These interactions are essential for IgG’s effector functions, including phagocytosis, antibody-dependent cellular cytotoxicity, and complement fixation.
Biological Role
Immune Defense
IgG plays a pivotal role in both innate and adaptive immunity. It neutralizes toxins and viral particles, preventing cell entry. By opsonizing bacteria and fungi, IgG marks them for phagocytosis by macrophages and neutrophils. IgG also activates the classical complement pathway through C1q binding, resulting in membrane attack complex formation and lysis of pathogens. Additionally, IgG facilitates antibody-dependent cellular cytotoxicity by engaging FcγRIII on natural killer cells, leading to targeted cell death.
Maternal Transfer
The neonatal Fc receptor (FcRn) mediates selective transport of IgG across the syncytiotrophoblast, enabling the transfer of maternal antibodies to the fetus. This process confers passive immunity against circulating pathogens during the first months of life. The efficiency of transfer varies among IgG subclasses, with IgG1 and IgG4 exhibiting the highest transplacental passage.
Clinical Significance
Diagnostic Use
Quantitative measurement of serum IgG levels assists in diagnosing immunoglobulin deficiencies, autoimmune disorders, and chronic infections. IgG subclass testing can identify selective deficiencies that predispose individuals to specific infections, such as recurrent sinopulmonary disease in IgG2 deficiency. Autoantibody panels, including IgG autoantibodies against neuronal antigens, are employed to diagnose neurological autoimmune disorders.
Therapeutic Applications
Monoclonal IgG antibodies constitute a major class of biologic therapeutics, targeting cancers, autoimmune diseases, and infectious pathogens. IgG1-based antibodies are favored for their potent effector functions, whereas IgG4 variants are preferred for conditions requiring minimal Fc-mediated activity. Additionally, intravenous immunoglobulin (IVIG) therapy, composed of pooled IgG from donors, is used to treat primary immunodeficiency and autoimmune conditions through mechanisms involving FcRn modulation and anti-idiotypic antibodies.
IgG in Disease
Infections
Deficiencies in IgG or particular subclasses increase susceptibility to specific pathogens. For example, IgG2 deficiency correlates with recurrent encapsulated bacterial infections, while IgG4 deficiency may predispose to chronic mucosal infections. Elevated IgG responses also reflect ongoing infections; IgG serology is routinely employed for diagnosing viral diseases such as hepatitis B and HIV, and for assessing exposure to pathogens like Mycobacterium tuberculosis.
Autoimmune Conditions
IgG autoantibodies are central to diseases such as systemic lupus erythematosus, rheumatoid arthritis, and myasthenia gravis. In these conditions, IgG binds to self-antigens, forming immune complexes that deposit in tissues, trigger complement activation, and recruit inflammatory cells. Measurement of specific IgG autoantibodies informs diagnosis, disease activity monitoring, and therapeutic decisions.
Congenital Disorders
Neonatal Fc receptor (FcRn) mutations impair IgG transport, leading to severe IgG deficiency in infants. Similarly, inherited defects in the IgG heavy chain gene cluster cause agammaglobulinemia, characterized by markedly reduced IgG and susceptibility to life-threatening infections.
Production and Engineering
Recombinant IgG
Recombinant DNA technology enables large-scale production of monoclonal IgG antibodies in mammalian cell lines such as CHO and HEK293. Expression vectors encode the heavy and light chain genes, and culture conditions are optimized for yield and product quality. Glycosylation patterns are carefully controlled, as they influence Fc receptor binding and pharmacokinetics.
Fc Engineering
Modifications to the Fc domain, such as point mutations or glycoengineering, alter effector functions. Enhancements in FcγR affinity increase antibody-dependent cellular cytotoxicity, useful in oncology. Conversely, mutations that reduce FcγR binding minimize inflammatory responses, advantageous for treating autoimmune diseases. Glycoengineering also affects neonatal Fc receptor interaction, thereby extending serum half-life.
Biosimilars
Biosimilar IgG products, designed to closely resemble approved biologics, are developed through rigorous comparative studies. They provide cost-effective alternatives for chronic conditions, expanding patient access. Regulatory agencies require demonstration of similar efficacy, safety, and immunogenicity profiles.
Measurement Methods
Enzyme-Linked Immunosorbent Assay (ELISA)
ELISA detects and quantifies IgG or specific IgG subclasses using antigen-coated microplates. The assay relies on enzyme-labeled secondary antibodies that produce a colorimetric readout proportional to IgG concentration. ELISA is widely employed for diagnostic serology, vaccine response assessment, and autoantibody profiling.
Nephelometry and Turbidimetry
These immunoassay techniques measure changes in light scattering caused by immune complex formation. Nephelometry is particularly suited for measuring total IgG concentrations in serum, whereas turbidimetry offers a simpler alternative for routine clinical labs.
Mass Spectrometry
Advanced mass spectrometric methods enable precise quantification of IgG glycoforms and subclass distribution. Such analyses provide insights into functional implications of glycosylation and aid in the development of engineered antibodies.
Regulatory Aspects
IgG-based therapeutics and diagnostic assays undergo stringent evaluation by regulatory authorities such as the FDA and EMA. Clinical trials assess safety, efficacy, pharmacokinetics, and immunogenicity. Post‑marketing surveillance monitors adverse events and long-term outcomes. For IVIG products, donor screening and rigorous purification processes minimize the risk of pathogen transmission.
Recent Research Trends
IgG in SARS‑CoV‑2 Infection
Serological studies measuring IgG antibodies against the spike protein provide information on exposure, vaccine response, and immune memory. The durability of IgG responses, as well as the role of neutralizing versus non‑neutralizing IgG, remains an active area of investigation.
IgG Glycosylation
Alterations in Fc glycosylation, such as fucosylation or sialylation levels, modulate IgG effector functions and inflammatory potential. Research explores therapeutic manipulation of glycosylation to enhance anti‑tumor efficacy or dampen autoimmune inflammation.
FcRn Modulation
Targeting FcRn offers strategies to extend IgG half-life or accelerate IgG clearance. Small molecules, peptides, and engineered antibodies that disrupt FcRn–IgG interactions are under development for treating autoimmunity and for improving pharmacokinetics of therapeutic antibodies.
Future Directions
Emerging technologies such as CRISPR‑Cas9 gene editing may enable precise modifications of IgG genes for therapeutic purposes. Single‑cell sequencing of B‑cell repertoires will deepen understanding of IgG diversity and antigen specificity. Integration of artificial intelligence in antibody design is accelerating the creation of next‑generation IgG therapeutics with optimized efficacy and reduced immunogenicity. Continued exploration of IgG biology promises advances in immunotherapy, infectious disease control, and precision medicine.
See also
- Antibody
- Fc receptor
- Neonatal Fc receptor
- Monoclonal antibody
- Intravenous immunoglobulin
- Immunoglobulin M
- Immunoglobulin A
No comments yet. Be the first to comment!